Difference between revisions of "Aplastic anemia"
Jump to navigation
Jump to search
(Created page with "'''Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.''' Is ...") |
m |
||
| Line 3: | Line 3: | ||
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]]. | Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]]. | ||
| + | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
| + | |- | ||
| + | |<div style="background-color: #66FF66; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} regimens on this page</b></font></div> | ||
| + | <div style="background-color: #66CCFF; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} variants on this page</b></font></div> | ||
| + | |} | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
| Line 9: | Line 14: | ||
=Relapsed/Refractory= | =Relapsed/Refractory= | ||
| − | ==Eltrombopag (Promacta)== | + | ==Eltrombopag (Promacta) {{#subobject:6a217b|Regimen=1}}== |
| + | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
| + | |- | ||
| + | |[[#toc|back to top]] | ||
| + | |} | ||
| − | ===Regimen, Olnes et al. 2012; Desmond et al. 2013=== | + | ===Regimen, Olnes et al. 2012; Desmond et al. 2013 {{#subobject:ca8fc4|Variant=1}}=== |
<span | <span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
| Line 19: | Line 28: | ||
border-style:solid;">Non-randomized</span> | border-style:solid;">Non-randomized</span> | ||
| − | *[[Eltrombopag (Promacta)]] 50 mg PO once per day, increased by 25 mg every 2 weeks until platelet count > 20,000 per | + | *[[Eltrombopag (Promacta)]] 50 mg PO once per day, increased by 25 mg every 2 weeks until platelet count > 20,000 per µL or maximum of 150 mg daily dose |
===References=== | ===References=== | ||
# Olnes MJ, Scheinberg P, Calvo KR, Desmond R, Tang Y, Dumitriu B, Parikh AR, Soto S, Biancotto A, Feng X, Lozier J, Wu CO, Young NS, Dunbar CE. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012 Jul 5;367(1):11-9. Erratum in: N Engl J Med. 2012 Jul 19;367(3):284. [http://www.nejm.org/doi/full/10.1056/NEJMoa1200931#t=article link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22762314 PubMed] | # Olnes MJ, Scheinberg P, Calvo KR, Desmond R, Tang Y, Dumitriu B, Parikh AR, Soto S, Biancotto A, Feng X, Lozier J, Wu CO, Young NS, Dunbar CE. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012 Jul 5;367(1):11-9. Erratum in: N Engl J Med. 2012 Jul 19;367(3):284. [http://www.nejm.org/doi/full/10.1056/NEJMoa1200931#t=article link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22762314 PubMed] | ||
# '''Update:''' Desmond R, Townsley DM, Dumitriu B, Olnes MJ, Scheinberg P, Bevans M, Parikh AR, Broder K, Calvo KR, Wu CO, Young NS, Dunbar CE. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014 Mar 20;123(12):1818-25. Epub 2013 Dec 17. [http://bloodjournal.hematologylibrary.org/content/123/12/1818.full link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/24345753 PubMed] | # '''Update:''' Desmond R, Townsley DM, Dumitriu B, Olnes MJ, Scheinberg P, Bevans M, Parikh AR, Broder K, Calvo KR, Wu CO, Young NS, Dunbar CE. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014 Mar 20;123(12):1818-25. Epub 2013 Dec 17. [http://bloodjournal.hematologylibrary.org/content/123/12/1818.full link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/24345753 PubMed] | ||
Revision as of 03:05, 9 February 2015
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
9 regimens on this page
12 variants on this page
|
Initial therapy
Relapsed/Refractory
Eltrombopag (Promacta)
| back to top |
Regimen, Olnes et al. 2012; Desmond et al. 2013
Non-randomized
- Eltrombopag (Promacta) 50 mg PO once per day, increased by 25 mg every 2 weeks until platelet count > 20,000 per µL or maximum of 150 mg daily dose
References
- Olnes MJ, Scheinberg P, Calvo KR, Desmond R, Tang Y, Dumitriu B, Parikh AR, Soto S, Biancotto A, Feng X, Lozier J, Wu CO, Young NS, Dunbar CE. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012 Jul 5;367(1):11-9. Erratum in: N Engl J Med. 2012 Jul 19;367(3):284. link to original article contains verified protocol PubMed
- Update: Desmond R, Townsley DM, Dumitriu B, Olnes MJ, Scheinberg P, Bevans M, Parikh AR, Broder K, Calvo KR, Wu CO, Young NS, Dunbar CE. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014 Mar 20;123(12):1818-25. Epub 2013 Dec 17. link to original article contains verified protocol PubMed